FLGT NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

Fulgent Genetics Inc · Healthcare · Diagnostics & Research

Open interactive chart View report data Download investor PDF
Latest close 19.67 USD
-2.4% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is 1.2% above the Trend Line and sits at 35.3% of its 52-week range. The latest completed week returned -2.4%, after a -1.5% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 46/100 conviction, while the latest news-sentiment score is 51/100. Near-term considerations: volume confirmation is below normal; earnings are due in 0d.

Setup score 32 out of 100
Latest Close 19.67 USD 24 Jul 2026
1W Return -2.4% latest completed week
4W Return -1.5% short-term follow-through
12W Return 39.2% quarterly tape
Trend Breadth 55.8% 29 of 52 weeks active
Volume Ratio 0.6x vs 13-week average
What is working
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Next-week expectancy is negative at 42.97% based on similar historical setup states.
  • Activity pressure is weak, so confirmation is not yet broad enough.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -2.4% Latest completed week; four-week move -1.5%. Indicator stack 31/59 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Recent Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 42.97% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Volatility 46/100 conviction; expected move 20.3%. News sentiment 51/100 56 relevant articles in the latest sentiment read. Event risk 0d Next report is scheduled for 30 Jul 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is 1.2% above the Trend Line and sits at 35.3% of its 52-week range. The latest completed week returned -2.4%, after a -1.5% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.6x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.3612-week average 0.23

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure8/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.36Current proprietary activity-pressure read.
Buy signals1Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -1.5% over four weeks, 39.2% over 12 weeks, and 7.1% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-2.4%
4W-1.5%
12W39.2%
26W-29.3%
52W7.1%
Active trend streak0 weeks
Active weeks in one year29
Trend breadth55.8%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.50Latest activity-pressure read.
Pressure change-0.2%Four-week change in activity pressure.
Leadership-16.46Latest relative-leadership reading.
RS change12.5%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks weakly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 82% Model confidence 78%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength41/100Blend of value, momentum, and quality. Underlying universe rank 60; rank 1 is best.
Value73/100Relative valuation strength. Underlying universe rank 28; rank 1 is best.
Quality4/100Profitability and accounting quality. Underlying universe rank 97; rank 1 is best.
Momentum32/100Medium-term price momentum. Underlying universe rank 69; rank 1 is best.
Growth69/100Revenue and earnings growth. Underlying universe rank 32; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
1.7x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-12.2%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
38.7%
Gross profit retained from each unit of revenue.
Operating margin
-25.8%
Operating profit retained from revenue.
Free-cash-flow margin
-20.9%
Free cash flow generated from revenue.
Return on invested capital
-6.0%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
9.5%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-233.2%
Latest one-year free-cash-flow growth.
Piotroski F-score
4/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
8.5%
Net share repurchases relative to market value.
Shareholder yield
8.5%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.2x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

FLGT shows volatility options pressure with a 46/100 conviction score, put-call volume ratio of 1.08, expected move of 20.3%, and Sharemaestro trend signal inactive.

Conviction46/100
Expected move20.3%
Put/call volume1.08
Pressure6
Speculation76
Volatility96
Trend agreement64
Open options detail
Insider activity4 / 11

4 acquisitions and 11 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment51/100

Weighted news tone is neutral across 56 relevant articles.

6 positive · 45 neutral · 5 negative
Patient CapitalRecent

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

Recent buy signal in the last 8 weeks
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings0dNext report is scheduled for 30 Jul 2026; event risk rises as the date approaches.
Options expected move20.3%Nearest-chain priced movement where available.
52-week drawdown-36.6%Distance below the 52-week high.
13-week volatility7.0%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher12 of 2614 weeks finished lower.
Best week+13.0%Week of 8 May.
Worst week-33.9%Week of 27 Feb.
Latest week-2.4%Week of 24 Jul.

Shape of recent returns

Strong gains9
Modest gains3
Flat weeks0
Modest losses8
Sharp losses6
Recent vol7.0%13-week weekly-return volatility.
Base vol7.8%52-week weekly-return volatility.
Up/down split28/24Count of positive and negative weeks in the 52-week window.
Average skew5.3% / -5.1%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape27/100

Trend, activity pressure, participation, and risk combine to a 27/100 tape read.

 Indicator analysis29/100

Latest 12-week confirmation: trend 0/12, activity pressure 8/12, relative leadership 0/12.

Activity pressure 0.36; No reversal markers Next-Week ExpectancyNegative 42.97%

Next-week expectancy is negative with a 42.97% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors36/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 6; Small Cap Core rank 21 Patient CapitalRecent

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

Recent buy signal in the last 8 weeks Options52/100

FLGT shows volatility options pressure with a 46/100 conviction score, put-call volume ratio of 1.08, expected move of 20.3%, and Sharemaestro trend signal inactive.

Volatility · Volatility expansion watch · Expected move 20.3% Sentiment51/100

Weighted news tone is neutral across 56 relevant articles.

Fulgent Genetics (FLGT) to Release Earnings on Thursday Insiders4 / 11

4 acquisitions and 11 disposals in the latest 180-day insider tape.

 Earnings0d

Next report is scheduled for 30 Jul 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 202619.67 USD-2.4%19.44 USD22.03 USD0.50-16.461.2MOff
17 Jul 202620.16 USD-1.9%19.68 USD22.15 USD0.53-15.931.2MOff
10 Jul 202620.55 USD-1.4%19.93 USD22.28 USD0.47-17.991.2MOff
3 Jul 202620.85 USD4.5%20.15 USD22.40 USD0.46-15.601.0MOff
26 Jun 202619.96 USD10.9%20.38 USD22.50 USD0.50-18.821.6MOff
19 Jun 202618.00 USD-3.6%20.70 USD22.61 USD0.44-30.381.4MOff
12 Jun 202618.68 USD-2.5%21.10 USD22.73 USD0.36-26.341.4MOff
5 Jun 202619.15 USD5.6%21.45 USD22.85 USD0.17-23.312.9MOff
29 May 202618.14 USD6.0%21.69 USD22.97 USD-0.07-31.132.7MOff
22 May 202617.11 USD9.0%21.83 USD23.11 USD-0.34-33.722.4MOff
15 May 202615.70 USD-1.6%22.05 USD23.25 USD-0.57-38.972.4MOff
8 May 202615.96 USD13.0%22.28 USD23.40 USD-0.70-38.714.0MOff
1 May 202614.13 USD-13.4%22.50 USD23.52 USD-0.91-43.293.4MOff
24 Apr 202616.31 USD0.3%22.79 USD23.65 USD-0.97-34.261.7MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.